Research programme: anti-CD19 monoclonal antibodies - Glenmark Pharmaceuticals

Drug Profile

Research programme: anti-CD19 monoclonal antibodies - Glenmark Pharmaceuticals

Alternative Names: GBR-401

Latest Information Update: 21 Jan 2014

Price : $50

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Class Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; CD19 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Leukaemia; Lymphoma

Most Recent Events

  • 21 Jan 2014 Discontinued - Preclinical for Leukaemia and Lymphoma in Switzerland (Parenteral) prior to January 2014
  • 12 Nov 2011 Final pharmacodynamics data from a preclinical study in cancer presented at the 23rd International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2011) .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top